This is an aggregated industry headline. Read the full story at BioPharma Dive →
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer's data
Novo's latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
By BioPharma Dive
· Sep 25, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
AJMC reported that Medicare drug price negotiations are yielding uneven out-of-pocket savings. The policy sign…
The WeekPharmaceutical Technology ↗
China's NMPA has approved the MAA for Foresee Pharmaceuticals' Camcevi 42 mg to treat adult patients with adva…
The WeekKFF Health News ↗
Health care's AI future is being built right now. The open question is "for whom?" Dr. Uché Blackstock - emerg…